Collaborative Transformation
Revolutionizing Healthcare Together
UNEXPECTED PARTNERSHIPS + HEALTHCARE INNOVATION > BUSINESS AS USUAL
Today’s healthcare and life sciences worlds are marked by uncommon disruption. But as unexpected partners join forces to innovate in bold and surprising ways, they also face some of healthcare’s toughest challenges. We’re here to help. At McDermott, we believe the power of collaboration will continue to move the industry forward. We call it Collaborative Transformation and our special brand of legal experience, rooted in decades of experience and powered by original thinking, is calibrated to overcome challenges and propel your success. Our renowned health and life sciences experience uniquely positions us to help you thrive in the many types of industry deals taking place throughout the world.
Today’s healthcare and life sciences worlds are marked by uncommon disruption. But as unexpected partners join forces to innovate in bold and surprising ways, they also face some of healthcare’s toughest challenges. We’re here to help. At McDermott, we believe the power of collaboration will continue to move the industry forward. We call it Collaborative Transformation and our special brand of legal experience, rooted in decades of experience and powered by original thinking, is calibrated to overcome challenges and propel your success. Our renowned health and life sciences experience uniquely positions us to help you thrive in the many types of industry deals taking place throughout the world.
FACILITATING CONNECTIONS WITH PURPOSE.
We’re crafters of partnerships who know coming up with the big idea is just the beginning. We get to work, translating inventive thinking into practical solutions and implementation plans. As a result, our clients are already transforming the delivery of healthcare and life sciences solutions.
BIOLOGICS MANUFACTURER + (US REGULATIONS + UK REGULATIONS) = DECADE OF REGULATORY STRATEGY
A company that manufactures biologicals sold as prescription medications around the world sought to understand the global risks related to demand for its products. Our team of lawyers and consultants mapped out the landscape of drug and biologic reimbursement paradigms in the United States and large European countries, including potential changes that may affect these paradigms over the next 10 years.
EUROPEAN FINANCIAL INSTITUTION + US REIMBURSEMENT PARADIGMS = EUROPEAN BIOTECH US REVENUE ANALYSIS
A European financial institution needed insight into how reimbursement paradigms in the United States may affect European biotech companies that rely on US revenue in their business models. We delivered comprehensive information to assist the financial institution with its analyses.
EUROPEAN DIAGNOSTICS COMPANY + US PRODUCT MARKETING ANALYSIS = SUPPORTING MARKET EXPANSION
A European diagnostics company that developed and launched a cancer test in Europe wanted to market the test in the United States. We provided guidance on the use of clinical and analytical evidence to support reimbursement, applying the ample evidence already collected in the development of the European assay where possible. We also advised where data obtained from the US laboratory would be necessary.
BIOLOGICS MANUFACTURER + (US REGULATIONS + UK REGULATIONS) = DECADE OF REGULATORY STRATEGY
A company that manufactures biologicals sold as prescription medications around the world sought to understand the global risks related to demand for its products. Our team of lawyers and consultants mapped out the landscape of drug and biologic reimbursement paradigms in the United States and large European countries, including potential changes that may affect these paradigms over the next 10 years.
EUROPEAN FINANCIAL INSTITUTION + US REIMBURSEMENT PARADIGMS = EUROPEAN BIOTECH US REVENUE ANALYSIS
A European financial institution needed insight into how reimbursement paradigms in the United States may affect European biotech companies that rely on US revenue in their business models. We delivered comprehensive information to assist the financial institution with its analyses.
EUROPEAN DIAGNOSTICS COMPANY + US PRODUCT MARKETING ANALYSIS = SUPPORTING MARKET EXPANSION
A European diagnostics company that developed and launched a cancer test in Europe wanted to market the test in the United States. We provided guidance on the use of clinical and analytical evidence to support reimbursement, applying the ample evidence already collected in the development of the European assay where possible. We also advised where data obtained from the US laboratory would be necessary.
(CVS + $70B cash and stock) + Aetna = Industry Transformation
(CVS + $70B CASH AND STOCK) + AETNA = INDUSTRY TRANSFORMATION
McDermott is one of the firms that has advised CVS Health in connection with its $69 billion purchase of Aetna. The transaction, one of this year's largest M&A deals, is expected to transform the US healthcare sector. Learn More »
Ascension x Centene = MA Plans
ASCENSION x CENTENE = MA PLANS
McDermott represented Ascension, the nation’s largest non-profit health system and the world's largest Catholic health system, in its joint venture with health insurer Centene to own and operate Medicare Advantage plans. Through the joint venture MA plans will be established as a preferred model for the respective systems and affiliates for Centene and Ascension in multiple geographic markets beginning in 2020.
The Carle Foundation x University of Illinois = Healthcare Education, Enhanced
THE CARLE FOUNDATION x UNIVERSITY OF ILLINOIS = HEALTHCARE EDUCATION, ENHANCED
McDermott advised The Carle Foundation in its unique partnership with the University of Illinois to develop a highly-focused college of medicine, the Carle Illinois College of Medicine. This new medical school will focus on the intersection of engineering and medicine, bringing together respected healthcare and academic systems to help develop future healthcare leaders.
(CVS + $70B CASH AND STOCK) + AETNA = INDUSTRY TRANSFORMATION
McDermott is one of the firms that has advised CVS Health in connection with its $69 billion purchase of Aetna. The transaction, one of this year's largest M&A deals, is expected to transform the US healthcare sector. Learn More »
ASCENSION x CENTENE = MA PLANS
McDermott represented Ascension, the nation’s largest non-profit health system and the world's largest Catholic health system, in its joint venture with health insurer Centene to own and operate Medicare Advantage plans. Through the joint venture MA plans will be established as a preferred model for the respective systems and affiliates for Centene and Ascension in multiple geographic markets beginning in 2020.
THE CARLE FOUNDATION x UNIVERSITY OF ILLINOIS = HEALTHCARE EDUCATION, ENHANCED
McDermott advised The Carle Foundation in its unique partnership with the University of Illinois to develop a highly-focused college of medicine, the Carle Illinois College of Medicine. This new medical school will focus on the intersection of engineering and medicine, bringing together respected healthcare and academic systems to help develop future healthcare leaders.
Read 
The most complex ventures require the most precise attention. Our unmatched health law team can guide you through the transaction. Our regulatory, reimbursement and operational legal experience, coupled with our drive to dig in and roll up our sleeves, drives us to find innovative answers to complex problems and solve the world’s big health issues alongside our clients.
Articles
Watch 
Watch to learn how you can take action to pursue innovation, hear about novel partnerships in action and more
Precision Health Possibilities and Pitfalls: Reimbursement and Regulatory Issues
focus on innovation centers:
Innovation Centers activate a culture of transformation across your hospital or health system, inspiring ideas and sparking solutions from the inside out. However, with innovation comes the enhanced need for an experienced legal team to help you navigate the many regulatory, legal and business requirements you will come across.
New Pathways + New Geographies = Market Access Solutions
We evaluate the market to provide a full opportunity and risk analysis with strategic guidance on reimbursement options, implementation and market entry in order to best position you for success.
Listen 
We’re always looking at what’s next. Hear how you can transform healthcare and life sciences through unexpected partnerships, unique collaborations and industry-changing deals.
Restructuring and Bankruptcy
The Evolving Role of Insurance in Private Equity Investments
Analyzing Shifts in Healthcare Private Equity Trends
Key Private Equity Investment Opportunities in 2021
Macro Trends in Post-Pandemic Private Equity Investments
A Lender’s Perspective on Healthcare PE Deals
Clearing Regulatory Hurdles in Public Hospital M&A
Key Payor Changes Affecting Healthcare Private Equity
Healthcare Private Equity Opportunities Under the New Administration
ABOUT THE TEAM
We understand the need for speed in the health and life sciences landscape. Rather than wait for change to happen, we stand ready at the forefront of innovation. Our cross-practice team offers unmatched legal experience and support to anticipate potential change, quickly adapt, and keep driving you forward, all while balancing regulatory, technological and structural needs. Whether your collaboration is large or small there are several legal considerations, you will need to address – we’re here to help with all the legal aspects of your merger, acquisition, cross-border partnership, joint venture or unique collaboration.
